Joel Greenblatt’s Dr. Reddy's Laboratories RDY Stock Holding History

Joel Greenblatt’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-16,445	Closed	-$1.12M	–	1401
2023 Q2	$1.12M	Buy	+16,445	New	+$192K	0.02%	734

Other funds holding RDY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Joel Greenblatt's RDY Position: Q3 2023 in Review

Joel Greenblatt sold out of Dr. Reddy's Laboratories (RDY) in Q3 2023, closing a stake of 16,445 shares — an estimated $1.12M sold.

Joel Greenblatt first reported a position in RDY in Q2 2023 and held it in 1 quarter. The position peaked at $1.12M in Q2 2023. 212 funds tracked by Wall St. Rank hold RDY as of Q3 2023.

Joel Greenblatt reported no remaining Dr. Reddy's Laboratories position as of Q3 2023 after selling out during the quarter.
Joel Greenblatt sold 16,445 Dr. Reddy's Laboratories shares in Q3 2023, an estimated $1.12M.
Joel Greenblatt first reported a position in Dr. Reddy's Laboratories in Q2 2023 and held it in 1 quarter.
Joel Greenblatt's Dr. Reddy's Laboratories position peaked at $1.12M in Q2 2023.
212 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2023.

Based on Gotham Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.